Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Antitumor effect of insulin-like growth factor-1 receptor inhibition in head and neck squamous cell carcinoma.

Lehman CE, Khalil AA, Axelrod MJ, Dougherty MI, Schoeff SS, Taniguchi LE, Mendez RE, David AP, McGarey PO Jr.,, Hubbard MA, Donaldson L, Frierson HF Jr.,, Stelow EB, Bekiranov S, Wulfkuhle JD, Petricoin EF, Gioeli DG, Jameson MJ.

Laryngoscope. 2019 Aug 21. doi: 10.1002/lary.28236. [Epub ahead of print]

PMID:
31433065
2.

Discovery of a novel long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth.

Ta HQ, Whitworth H, Yin Y, Conaway M, Frierson HF Jr, Campbell MJ, Raj GV, Gioeli D.

Mol Cancer. 2019 Jun 28;18(1):113. doi: 10.1186/s12943-019-1039-6.

3.

Development of a multicellular pancreatic tumor microenvironment system using patient-derived tumor cells.

Gioeli D, Snow CJ, Simmers MB, Hoang SA, Figler RA, Allende JA, Roller DG, Parsons JT, Wulfkuhle JD, Petricoin EF, Bauer TW, Wamhoff BR.

Lab Chip. 2019 Mar 27;19(7):1193-1204. doi: 10.1039/c8lc00755a.

PMID:
30839006
4.

Survivin in Insulin-Like Growth Factor-Induced Resistance to Lapatinib in Head and Neck Squamous Carcinoma Cells.

Lehman CE, Mendez RE, Dougherty MI, Allak A, Adejumo OL, Taniguchi LE, Khalil A, Gioeli DG, Jameson MJ.

Front Oncol. 2019 Jan 23;9:13. doi: 10.3389/fonc.2019.00013. eCollection 2019.

5.

Effect of Adipose-Derived Stem Cells on Head and Neck Squamous Cell Carcinoma.

Danan D, Lehman CE, Mendez RE, Langford B, Koors PD, Dougherty MI, Peirce SM, Gioeli DG, Jameson MJ.

Otolaryngol Head Neck Surg. 2018 May;158(5):882-888. doi: 10.1177/0194599817750361. Epub 2018 Jan 9.

PMID:
29313435
6.

Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha.

Olmez I, Love S, Xiao A, Manigat L, Randolph P, McKenna BD, Neal BP, Boroda S, Li M, Brenneman B, Abounader R, Floyd D, Lee J, Nakano I, Godlewski J, Bronisz A, Sulman EP, Mayo M, Gioeli D, Weber M, Harris TE, Purow B.

Neuro Oncol. 2018 Jan 22;20(2):192-202. doi: 10.1093/neuonc/nox119.

7.

αvβ6 Integrin Promotes Castrate-Resistant Prostate Cancer through JNK1-Mediated Activation of Androgen Receptor.

Lu H, Wang T, Li J, Fedele C, Liu Q, Zhang J, Jiang Z, Jain D, Iozzo RV, Violette SM, Weinreb PH, Davis RJ, Gioeli D, FitzGerald TJ, Altieri DC, Languino LR.

Cancer Res. 2016 Sep 1;76(17):5163-74. doi: 10.1158/0008-5472.CAN-16-0543. Epub 2016 Jul 22.

8.

Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.

Benamar M, Guessous F, Du K, Corbett P, Obeid J, Gioeli D, Slingluff CL Jr, Abbas T.

EBioMedicine. 2016 Aug;10:85-100. doi: 10.1016/j.ebiom.2016.06.023. Epub 2016 Jun 16.

9.

Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.

Roller DG, Capaldo B, Bekiranov S, Mackey AJ, Conaway MR, Petricoin EF, Gioeli D, Weber MJ.

Oncotarget. 2016 Jan 19;7(3):2734-53. doi: 10.18632/oncotarget.6548.

10.

Preventing the Androgen Receptor N/C Interaction Delays Disease Onset in a Mouse Model of SBMA.

Zboray L, Pluciennik A, Curtis D, Liu Y, Berman-Booty LD, Orr C, Kesler CT, Berger T, Gioeli D, Paschal BM, Merry DE.

Cell Rep. 2015 Dec 15;13(10):2312-23. doi: 10.1016/j.celrep.2015.11.019. Epub 2015 Dec 7.

11.

Checkpoint Kinase 2 Negatively Regulates Androgen Sensitivity and Prostate Cancer Cell Growth.

Ta HQ, Ivey ML, Frierson HF Jr, Conaway MR, Dziegielewski J, Larner JM, Gioeli D.

Cancer Res. 2015 Dec 1;75(23):5093-105. doi: 10.1158/0008-5472.CAN-15-0224. Epub 2015 Nov 16.

12.

Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma.

Capaldo BJ, Roller D, Axelrod MJ, Koeppel AF, Petricoin EF, Slingluff CL Jr, Weber MJ, Mackey AJ, Gioeli D, Bekiranov S.

PLoS One. 2015 Sep 25;10(9):e0138210. doi: 10.1371/journal.pone.0138210. eCollection 2015.

13.

Cell-cycle-dependent regulation of androgen receptor function.

Koryakina Y, Knudsen KE, Gioeli D.

Endocr Relat Cancer. 2015 Apr;22(2):249-64. doi: 10.1530/ERC-14-0549. Epub 2015 Feb 17.

14.

The convergence of DNA damage checkpoint pathways and androgen receptor signaling in prostate cancer.

Ta HQ, Gioeli D.

Endocr Relat Cancer. 2014 Oct;21(5):R395-407. doi: 10.1530/ERC-14-0217. Epub 2014 Aug 5. Review.

15.

Synergistic apoptosis in head and neck squamous cell carcinoma cells by co-inhibition of insulin-like growth factor-1 receptor signaling and compensatory signaling pathways.

Axelrod MJ, Mendez RE, Khalil A, Leimgruber SS, Sharlow ER, Capaldo B, Conaway M, Gioeli DG, Weber MJ, Jameson MJ.

Head Neck. 2015 Dec;37(12):1722-32. doi: 10.1002/hed.23822. Epub 2015 Apr 6.

PMID:
24986420
16.

p70S6 kinase is a critical node that integrates HER-family and PI3 kinase signaling networks.

Axelrod MJ, Gordon V, Mendez RE, Leimgruber SS, Conaway MR, Sharlow ER, Jameson MJ, Gioeli DG, Weber MJ.

Cell Signal. 2014 Aug;26(8):1627-35. doi: 10.1016/j.cellsig.2014.03.013. Epub 2014 Mar 21.

17.

Androgen receptor phosphorylation: biological context and functional consequences.

Koryakina Y, Ta HQ, Gioeli D.

Endocr Relat Cancer. 2014 Aug;21(4):T131-45. doi: 10.1530/ERC-13-0472. Epub 2014 Jan 14. Review.

18.

Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanisms.

Axelrod M, Gordon VL, Conaway M, Tarcsafalvi A, Neitzke DJ, Gioeli D, Weber MJ.

Oncotarget. 2013 Apr;4(4):622-35.

19.

Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma.

Roller DG, Axelrod M, Capaldo BJ, Jensen K, Mackey A, Weber MJ, Gioeli D.

Mol Cancer Ther. 2012 Nov;11(11):2505-15. doi: 10.1158/1535-7163.MCT-12-0461. Epub 2012 Sep 7.

20.

Identification of kinases regulating prostate cancer cell growth using an RNAi phenotypic screen.

Whitworth H, Bhadel S, Ivey M, Conaway M, Spencer A, Hernan R, Holemon H, Gioeli D.

PLoS One. 2012;7(6):e38950. doi: 10.1371/journal.pone.0038950. Epub 2012 Jun 27.

21.

Post-translational modification of the androgen receptor.

Gioeli D, Paschal BM.

Mol Cell Endocrinol. 2012 Apr 16;352(1-2):70-8. doi: 10.1016/j.mce.2011.07.004. Epub 2011 Jul 24.

PMID:
21820033
22.

Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration-resistant prostate cancer.

Gioeli D, Wunderlich W, Sebolt-Leopold J, Bekiranov S, Wulfkuhle JD, Petricoin EF 3rd, Conaway M, Weber MJ.

Mol Cancer Ther. 2011 Sep;10(9):1581-90. doi: 10.1158/1535-7163.MCT-10-1033. Epub 2011 Jun 28.

23.

MST1 is a multifunctional caspase-independent inhibitor of androgenic signaling.

Cinar B, Collak FK, Lopez D, Akgul S, Mukhopadhyay NK, Kilicarslan M, Gioeli DG, Freeman MR.

Cancer Res. 2011 Jun 15;71(12):4303-13. doi: 10.1158/0008-5472.CAN-10-4532. Epub 2011 Apr 21.

24.

CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation.

Gordon V, Bhadel S, Wunderlich W, Zhang J, Ficarro SB, Mollah SA, Shabanowitz J, Hunt DF, Xenarios I, Hahn WC, Conaway M, Carey MF, Gioeli D.

Mol Endocrinol. 2010 Dec;24(12):2267-80. doi: 10.1210/me.2010-0238. Epub 2010 Oct 27.

25.

Matrix rigidity regulates cancer cell growth and cellular phenotype.

Tilghman RW, Cowan CR, Mih JD, Koryakina Y, Gioeli D, Slack-Davis JK, Blackman BR, Tschumperlin DJ, Parsons JT.

PLoS One. 2010 Sep 23;5(9):e12905. doi: 10.1371/journal.pone.0012905.

26.

Karyopherin alpha7 (KPNA7), a divergent member of the importin alpha family of nuclear import receptors.

Kelley JB, Talley AM, Spencer A, Gioeli D, Paschal BM.

BMC Cell Biol. 2010 Aug 11;11:63. doi: 10.1186/1471-2121-11-63.

27.

Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.

Liu Y, Karaca M, Zhang Z, Gioeli D, Earp HS, Whang YE.

Oncogene. 2010 Jun 3;29(22):3208-16. doi: 10.1038/onc.2010.103. Epub 2010 Apr 12.

28.

The promise of novel androgen receptor antagonists.

Gioeli DG.

Cell Cycle. 2010 Feb 1;9(3):440-1. Epub 2010 Feb 1. No abstract available.

PMID:
20130446
29.

FKBP51 promotes assembly of the Hsp90 chaperone complex and regulates androgen receptor signaling in prostate cancer cells.

Ni L, Yang CS, Gioeli D, Frierson H, Toft DO, Paschal BM.

Mol Cell Biol. 2010 Mar;30(5):1243-53. doi: 10.1128/MCB.01891-08. Epub 2010 Jan 4.

30.

The neuroendocrine-derived peptide parathyroid hormone-related protein promotes prostate cancer cell growth by stabilizing the androgen receptor.

DaSilva J, Gioeli D, Weber MJ, Parsons SJ.

Cancer Res. 2009 Sep 15;69(18):7402-11. doi: 10.1158/0008-5472.CAN-08-4687. Epub 2009 Aug 25. Erratum in: Cancer Res. 2009 Oct 1;69(19):7894.

31.

SUMO-specific protease 1 (SENP1) reverses the hormone-augmented SUMOylation of androgen receptor and modulates gene responses in prostate cancer cells.

Kaikkonen S, Jääskeläinen T, Karvonen U, Rytinki MM, Makkonen H, Gioeli D, Paschal BM, Palvimo JJ.

Mol Endocrinol. 2009 Mar;23(3):292-307. doi: 10.1210/me.2008-0219. Epub 2008 Dec 30.

32.

Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.

Wu Z, Gioeli D, Conaway M, Weber MJ, Theodorescu D.

Prostate. 2008 Jun 15;68(9):935-44. doi: 10.1002/pros.20745.

33.

Activation of the DNA-dependent protein kinase stimulates nuclear export of the androgen receptor in vitro.

Shank LC, Kelley JB, Gioeli D, Yang CS, Spencer A, Allison LA, Paschal BM.

J Biol Chem. 2008 Apr 18;283(16):10568-80. doi: 10.1074/jbc.M800810200. Epub 2008 Feb 12.

34.

Rap2 regulates androgen sensitivity in human prostate cancer cells.

Bigler D, Gioeli D, Conaway MR, Weber MJ, Theodorescu D.

Prostate. 2007 Oct 1;67(14):1590-9.

PMID:
17918750
35.

Ruthenium(II) tris(bipyridine)-centered poly(ethylenimine) for gene delivery.

Fiore GL, Edwards JM, Payne SJ, Klinkenberg JL, Gioeli DG, Demas JN, Fraser CL.

Biomacromolecules. 2007 Sep;8(9):2829-35. Epub 2007 Jul 31.

PMID:
17663530
36.

Subcellular localization modulates activation function 1 domain phosphorylation in the androgen receptor.

Kesler CT, Gioeli D, Conaway MR, Weber MJ, Paschal BM.

Mol Endocrinol. 2007 Sep;21(9):2071-84. Epub 2007 Jun 19.

PMID:
17579212
37.

Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor.

Kraus S, Gioeli D, Vomastek T, Gordon V, Weber MJ.

Cancer Res. 2006 Nov 15;66(22):11047-54.

38.

Integration of rapid signaling events with steroid hormone receptor action in breast and prostate cancer.

Lange CA, Gioeli D, Hammes SR, Marker PC.

Annu Rev Physiol. 2007;69:171-99. Review.

PMID:
17037979
39.

Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells.

Wu Z, Conaway M, Gioeli D, Weber MJ, Theodorescu D.

Prostate. 2006 Jul 1;66(10):1114-23.

PMID:
16637073
40.

Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization.

Gioeli D, Black BE, Gordon V, Spencer A, Kesler CT, Eblen ST, Paschal BM, Weber MJ.

Mol Endocrinol. 2006 Mar;20(3):503-15. Epub 2005 Nov 10.

PMID:
16282370
41.

Simian virus 40 small t antigen mediates conformation-dependent transfer of protein phosphatase 2A onto the androgen receptor.

Yang CS, Vitto MJ, Busby SA, Garcia BA, Kesler CT, Gioeli D, Shabanowitz J, Hunt DF, Rundell K, Brautigan DL, Paschal BM.

Mol Cell Biol. 2005 Feb;25(4):1298-308.

42.

Signal transduction in prostate cancer progression.

Gioeli D.

Clin Sci (Lond). 2005 Apr;108(4):293-308. Review.

PMID:
15603554
43.

The androgen receptor acetylation site regulates cAMP and AKT but not ERK-induced activity.

Fu M, Rao M, Wu K, Wang C, Zhang X, Hessien M, Yeung YG, Gioeli D, Weber MJ, Pestell RG.

J Biol Chem. 2004 Jul 9;279(28):29436-49. Epub 2004 Apr 30.

44.

Ras signaling in prostate cancer progression.

Weber MJ, Gioeli D.

J Cell Biochem. 2004 Jan 1;91(1):13-25. Review.

PMID:
14689577
45.

Transient, ligand-dependent arrest of the androgen receptor in subnuclear foci alters phosphorylation and coactivator interactions.

Black BE, Vitto MJ, Gioeli D, Spencer A, Afshar N, Conaway MR, Weber MJ, Paschal BM.

Mol Endocrinol. 2004 Apr;18(4):834-50. Epub 2003 Dec 18.

PMID:
14684849
46.
47.

Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells.

Bakin RE, Gioeli D, Bissonette EA, Weber MJ.

Cancer Res. 2003 Apr 15;63(8):1975-80.

48.

Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites.

Gioeli D, Ficarro SB, Kwiek JJ, Aaronson D, Hancock M, Catling AD, White FM, Christian RE, Settlage RE, Shabanowitz J, Hunt DF, Weber MJ.

J Biol Chem. 2002 Aug 9;277(32):29304-14. Epub 2002 May 15.

49.

Immunostaining for activated extracellular signal-regulated kinases in cells and tissues.

Gioeli D, Zecevic M, Weber MJ.

Methods Enzymol. 2001;332:343-53. No abstract available.

PMID:
11305109
50.

Analysis of oncogene, tumor suppressor gene, and chromosomal alterations in HeLa x osteosarcoma somatic cell hybrids.

Isfort RJ, Cody DB, Lovell GJ, Gioeli D, Weissman BE, Doersen CJ.

Mol Carcinog. 1999 May;25(1):30-41.

PMID:
10331742

Supplemental Content

Loading ...
Support Center